Last updated August 16, 2026
Key finding
The rate of confirmed hypoglycemic episodes was 86% higher (p < 0.0001) for IDegAsp versus IGlar.
This study compared the efficacy and safety of insulin degludec/insulin aspart with insulin glargine in insulin-naïve adults with type 2 diabetes. IDegAsp showed a significantly higher rate of hypoglycemic episodes but lower nocturnal hypoglycemia.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared the efficacy and safety of insulin degludec/insulin aspart with insulin glargine in insulin-naïve adults with type 2 diabetes. IDegAsp showed a significantly higher rate of hypoglycemic episodes but lower nocturnal hypoglycemia.
Understanding the safety profiles of insulin treatments is crucial for managing type 2 diabetes effectively. This study highlights the trade-offs between achieving glycemic control and the risk of hypoglycemia, which is a significant concern for patients and healthcare providers when choosing insulin therapy.
The study's population may not represent all insulin-naïve adults with type 2 diabetes. Potential confounding factors not measured could influence results. The trial duration may not capture long-term safety and efficacy.
Published in
Publication details and source links for this paper.
Ajay K, Edward F, Jonathan W, et al. Efficacy and Safety of Insulin Degludec/Insulin Aspart Compared with Insulin Glargine in Insulin-Naïve Adults with Type 2 Diabetes: A Randomized Controlled Trial. PLOS ONE. 2016;11(10):e0163350. doi:10.1371/journal.pone.0163350
Mean HbA1c decreased similarly in both IDegAsp and IGlar groups.
Mean fasting plasma glucose showed comparable reductions in both treatment groups.
The rate of confirmed hypoglycemic episodes was 86% higher for IDegAsp (p < 0.0001).
The rate of nocturnal hypoglycemia was 75% lower for IDegAsp (p < 0.0001).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Glargine U100, Insulin degludec and Fasting Plasma Glucose (FPG), HbA1c, Nocturnal hypoglycemia, and 1 more.
This study contributes evidence to
Primary intervention
Glargine U100
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
3
Related topics
8
Evidence pairs
645
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence relationship
Save evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Glargine U100 → Fasting Plasma Glucose (FPG)
Glargine U100 → Fasting Plasma Glucose (FPG)
Glargine U100 → Rate of confirmed hypoglycemic episodes
Glargine U100 → Rate of confirmed hypoglycemic episodes
Insulin degludec → Fasting Plasma Glucose (FPG)
Insulin degludec → Fasting Plasma Glucose (FPG)
Insulin degludec → Nocturnal hypoglycemia
Insulin degludec → Nocturnal hypoglycemia
Insulin degludec → Rate of confirmed hypoglycemic episodes
Insulin degludec → Rate of confirmed hypoglycemic episodes
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Therapies and HbA1c, Glargine U100 and Fasting Glucose.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Insulin Therapies
Contributes to Insulin Therapies evidence base.
All studies measuring Fasting Glucose
Measures Fasting Glucose as a key outcome.
All studies on Glargine U100
Contributes to Glargine U100 evidence base.
Jump to pre-filtered views in Evidence Explorer.
3 results
1 results
3 results
1 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
Insulin Therapies may improve Fasting Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.
Limitations
Insulin Therapies may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 13 supporting studies with consistent results and a positive effect signal.
Limitations
Current evidence does not show a clear benefit of Glargine U100 for Fasting Plasma Glucose (FPG).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Fasting Plasma Glucose (FPG)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Glargine U100 for HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
